Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (8719)	2/14/1999 10:19:00 PM
From: Slugger	Read Replies (1) \| Respond to of 17367

Not sure if anyone has posted this before, but lots of insiders buying towards the end of December: biz.yahoo.com Nice to know that if the ship sinks the captain and crew will go with us. :-I

To: Bluegreen who wrote (8719)	2/15/1999 1:42:00 AM
From: aknahow	Respond to of 17367

Bluegreen I considered Hassans statements important. I think you are right about Chiron but the buyer won't be PNU but rather Novaritis if it wants to. The same goes for GNE which Roache controls and IMUN which is already spoken for also. Perhaps AMGN, INCY, HGSY, LGND, CORR. I am still bewildered by such a blunt clear cut statement. Any other large pharma that had at least a passing interest in buying out biotechs will put renewed pressure on management to do more pre acquisition groundwork, at top speed. Any profitable biotech, or one with products on the market or in P III trials will probably at least get looked at. I am convinced that rotation into biotechs has already started. Follow IBD stats on price performance of 197 groups and "biotechs" now rank in 13 place. Regulation, financing and of course understanding the science present big risk.